Novel drug to slow cataracts on their path to causing blindness

September 5, 2011

The innovators behind commercialising a world-first drug to slow cataract growth and to delay cataracts forming, have been named as one of five finalists in The University of Queensland (UQ) Business School's $100,000 Enterprize business plan competition.

The drug being commercially developed by Adelaide-based Calpain Therapeutics targets a protein in the eye's tissue.

This , when activated by various triggers, including those associated with the body's ageing, causes the clouding of the eye's lens, known as a .

Severe cataracts are the leading cause of blindness around the world.

Although most cataracts develop as people get older, they can also be caused by diabetes, eye injury, exposure to from sunlight, long-term use of steroid medication, smoking and heavy drinking.

The International Agency for the Prevention of Blindness estimates that almost 18 million people are blind from cataracts.

Many of those are in the world's poorer regions.

Currently there are no drops or medications to prevent or reverse cataracts.

The only treatment is to have the cloudy lens surgically removed and replaced with a synthetic lens.

More than 200,000 cataract surgeries are performed in Australia each year and about 3.4 million a year in the United States.

There are often long waiting lists in public hospitals for the surgery.

Testing of the lead drug compound being advanced by Calpain Therapeutics has shown that it significantly slows cataract progression.

“Our drug could be either drops or a cream that you put in your eyes each night before you go to sleep,” says Calpain Therapeutics founding CEO and Managing Director, Dr. Tim Lovell.

“Through a routine eye exam, optometrists and ophthalmologists can see the early stages of a cataract forming, likely before the person has any idea they have it.

"Once it's detected, then you could start to use the drug to slow its progress.

“And because we know that if you have a cataract in one eye you will most likely get one in the other eye, you could start to apply the drug to both eyes, delaying the onset of a cataract in one while slowing the growth of the cataract that has been diagnosed.

“We see it as akin to brushing your teeth each day.

"You do that to prevent cavities. This would be a drop each day to prevent cataracts.''

A large team is behind the development of the drug.

The lead inventor is Professor Andrew Abell, Professor of Chemistry at Adelaide University, who has been working for the past decade on the class of compounds involved.

Dr. Tim Lovell has previously worked on drug design and development with global pharmaceutical company AstraZeneca and was most recently a business development manager at Bio Innovation SA in Adelaide.

He says winning the UQ Business School's Enterprize competition $100,000 prize would enable Calpain Therapeutics to do crucial clinical experiments.

“We have ophthalmologists on our advisory team who get very excited about what we are doing, because they haven't seen anything in their careers like this to delay the forming of cataracts, and which also has a possible secondary effect in protecting against other eye diseases,” Dr. Lovell says.

Since its inception in 2000, the Enterprize competition has assisted many successful businesses, including Fusion Sport, Codesion (formerly CVSDude), BakBalls, last year's winner Southern Innovation and finalist last year Vaxxas (which is pioneering the Nanopatch needle-free vaccine delivery system).

Related Stories

Recommended for you

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Too little vitamin D may hinder recovery of injured corneas

July 24, 2017
Injury or disease in combination with too little vitamin D can be bad for the window to your eyes.

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.